Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aditya Birla Capital Q4 FY26 Results | Wockhardt Q4 FY26 Results | Top Buzzing Stocks Today - Equitymaster
Aditya Birla Capital Q4 FY26 Results | Wockhardt Q4 FY26 Results | Top Buzzing Stocks TodayEquitymaster

Nippon India Mutual Fund raises stake in this healthcare stock. Do you own? - Mint
Nippon India Mutual Fund raises stake in this healthcare stock. Do you own?Mint

Q4 Results LIVE Updates: DMart shares down 4%, ideaForge Technologies up 16%; Ambuja report today
Q4 Results LIVE Updates: Amubja Cements, Manappuram Finance, Godrej Properties, Aditya Birla Capital, Tata Technologies, KEI Industries, Jindal Stainless, BHEL, Aarti Industries, Sobha, Quess Corp, Tata Chemicals, Wockhardt, are among the companies reporting their earnings today. Also watch for earnings reactions from Avenue Supermarts, Kotak Mahindra Bank, CDSL, NSDL, Zen Technologies, Mazagon Dock and others. Watch this space for all the LIVE earnings reactions.

Stock market today: Gift Nifty signals gap-up start; election results, India VIX to Q4 results — 7 stocks to buy or sell
Stock market today: Experts recommend these eight stocks to buy today —Sona Blw Precision Forgings, Sai Life Sciences, Reliance, SAIL, GPPL, Thermax, and Tata Capital
Where to invest now: SBI MF prefers large caps, pharma, PSU banks
Ruchit Mehta, Head of Research at SBI Mutual Fund, prefers CDMO and hospital plays within pharma, citing stronger growth prospects over generics. He sees large caps as attractive on valuations, while midcaps require selectivity amid earnings risks. PSU banks may outperform in the near term due to stronger loan growth, but asset quality risks could emerge over the next 2–3 quarters if global disruptions persist.

Sensex jumps 639 points, Nifty reclaims 24,100 as Reliance Industries, Sun Pharma lead rebound
BSE Sensex and NSE Nifty rebounded after three losing sessions, led by Sun Pharma, Reliance Industries and midcaps, with all sectoral indices ending higher
Sensex dives 850 pts, Nifty slips below 24,200 amid oil shock and weak global cues
The equity benchmark indices Sensex and Nifty tumbled on Thursday, extending losses for a second straight session. Firm crude oil prices and ongoing geopolitical tensions rattled sentiment. Brent crude surged for the fourth consecutive day to around $103 per barrel amid uncertainty over US-Iran talks and fresh concerns around the Strait of Hormuz. Weak Asian cues and persistent foreign fund outflows deepened the sell-off. The Nifty slipped below the 24,200 mark, dragged by auto, PSU banks and consumer durables stocks, while pharma and healthcare shares saw selective buying. Investors stayed cautious, closely tracking the ongoing Q4 earnings season for further triggers.
Nippon India Mutual Fund Increases Stake in Syngene International to 7.12% - scanx.trade
Nippon India Mutual Fund Increases Stake in Syngene International to 7.12%scanx.trade

Trade Setup for April 15: Nifty holds 23,500 support but bulls aim for a retest of 24,000
Wednesday's session will see stocks like ICICI Prudential Life, ICICI Prudential AMC, Just Dial react to their quarterly results, while names like LG Electronics India, Bharat Coking Coal, and Rubicon Research see their respective shareholder lock-ins end.
MF Favourites take a hit: 14 smallcap stocks slide up to 50% in 3 months
Despite rising mutual fund stakes, several smallcap stocks have plunged up to 47% in 2026, highlighting market uncertainty and raising questions on whether these beaten-down picks offer value or further downside.
Sun Pharmaceutical Industries Ltd eases for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1689.8, down 0.22% on the day as on 13:19 IST on the NSE. The stock jumped 1.41% in last one year as compared to a 3.17% rally in NIFTY and a 8.74% spurt in the Nifty Pharma index.
Sensex Today Trades Lower | Nifty Below 22,700 | Kotak Mahindra & Sun Pharma Top Losers - Equitymaster
Sensex Today Trades Lower | Nifty Below 22,700 | Kotak Mahindra & Sun Pharma Top LosersEquitymaster